ASX:1AD

Stock Analysis Report

Executive Summary

AdAlta Limited, a drug discovery and development company, develops protein therapeutics.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.

Share Price & News

How has AdAlta's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1AD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.2%

1AD

-1.0%

AU Biotechs

-1.0%

AU Market


1 Year Return

-56.6%

1AD

46.2%

AU Biotechs

16.2%

AU Market

Return vs Industry: 1AD underperformed the Australian Biotechs industry which returned 46.2% over the past year.

Return vs Market: 1AD underperformed the Australian Market which returned 16.2% over the past year.


Shareholder returns

1ADIndustryMarket
7 Day-4.2%-1.0%-1.0%
30 Day-4.2%5.7%-0.2%
90 Day-4.2%12.4%2.2%
1 Year-55.0%-56.6%47.9%46.2%21.9%16.2%
3 Year-33.8%-36.1%174.3%164.4%36.3%17.7%
5 Yearn/a222.1%201.2%52.7%18.3%

Price Volatility Vs. Market

How volatile is AdAlta's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AdAlta undervalued compared to its fair value and its price relative to the market?

2.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1AD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1AD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1AD is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1AD is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1AD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1AD is good value based on its PB Ratio (2.3x) compared to the AU Biotechs industry average (3.4x).


Next Steps

Future Growth

How is AdAlta forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

133.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1AD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: 1AD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 1AD's is expected to become profitable in the next 3 years.

Revenue vs Market: 1AD's revenue (112.4% per year) is forecast to grow faster than the Australian market (3.6% per year).

High Growth Revenue: 1AD's revenue (112.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1AD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has AdAlta performed over the past 5 years?

-28.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1AD has high quality earnings.

Growing Profit Margin: 1AD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1AD is unprofitable, and losses have increased over the past 5 years at a rate of -28.8% per year.

Accelerating Growth: Unable to compare 1AD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1AD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.5%).


Return on Equity

High ROE: 1AD has a negative Return on Equity (-79%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is AdAlta's financial position?


Financial Position Analysis

Short Term Liabilities: 1AD's short term assets (A$9.2M) exceeds its short term liabilities (A$1.8M)

Long Term Liabilities: 1AD has no long term liabilities


Debt to Equity History and Analysis

Debt Level: 1AD is debt free.

Reducing Debt: 1AD has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 1AD has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 1AD's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1AD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 1AD has less than a year of cash runway if free cash flow continues to reduce at historical rates of -34.5% each year


Next Steps

Dividend

What is AdAlta's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.4%markettop25%5.6%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 1AD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1AD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1AD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1AD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1AD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of AdAlta's salary, the management and board of directors tenure and is there insider trading?

2.1yrs

Average management tenure


CEO

Tim Oldham 0

0.08yrs

Tenure

0

Dr. Timothy Charles Oldham, also known as Tim, BSc(Hons), LLB(Hons), Ph.D., has been Chief Executive Officer and Managing Director and Director of AdAlta Limited since October 14, 2019. He served as Presid ...


Management Age and Tenure

2.1yrs

Average Tenure

Experienced Management: 1AD's management team is considered experienced (2.1 years average tenure).


Board Age and Tenure

4.3yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 1AD's board of directors are considered experienced (4.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellAU$71,55218 Sep 19
UBS Asset Management
EntityCompany
Shares529,843
Max PriceAU$0.14
BuyAU$273,50821 Aug 19
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares1,823,388
Max PriceAU$0.15
SellAU$208,89921 Aug 19
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares1,541,418
Max PriceAU$0.22
BuyAU$115,21429 Jul 19
City Castle Pty Ltd
EntityCompany
Shares720,000
Max PriceAU$0.31
SellAU$14,86528 Jul 19
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares87,557
Max PriceAU$0.22
BuyAU$1,176,75428 Jul 19
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares7,832,292
Max PriceAU$0.15
SellAU$20,66605 Jul 19
UBS Asset Management
EntityCompany
Shares128,892
Max PriceAU$0.16

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.9%.


Management Team

  • Tim Oldham

    CEO, MD & Director

    • Tenure: 0.08yrs
  • Mick Foley

    Chief Scientific Advisor & Chief Scientific Officer

    • Tenure: 0yrs
  • Dallas Hartman

    Chief Operating Officer

    • Tenure: 2.1yrs
  • Cameron Jones

    Company Secretary

    • Tenure: 2.5yrs

Board Members

  • John Chiplin (60yo)

    Independent Non-Executive Director

    • Tenure: 5.5yrs
    • Compensation: AU$45.00k
  • Bob Peach (63yo)

    Non-Executive Director

    • Tenure: 3yrs
    • Compensation: AU$50.31k
  • James Williams (49yo)

    Non-Executive Director

    • Tenure: 8.9yrs
    • Compensation: AU$45.00k
  • Liddy McCall

    Non-Executive Director

    • Tenure: 8.9yrs
    • Compensation: AU$45.00k
  • Paul Donald MacLeman (53yo)

    Chairman

    • Tenure: 0yrs
    • Compensation: AU$65.00k
  • Tim Oldham

    CEO, MD & Director

    • Tenure: 0.08yrs
  • Mick Foley

    Chief Scientific Advisor & Chief Scientific Officer

    • Tenure: 0yrs
  • Brian Richardson

    Scientific Advisor

    • Tenure: 0yrs
  • John Westwick

    Scientific Advisor

    • Tenure: 0yrs
  • Ros Wilson

    Non Executive Director

    • Tenure: 0.3yrs

Company Information

AdAlta Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AdAlta Limited
  • Ticker: 1AD
  • Exchange: ASX
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$18.827m
  • Shares outstanding: 163.71m
  • Website: https://www.adalta.com.au

Location

  • AdAlta Limited
  • 2 Park Drive
  • Unit 15
  • Bundoora
  • Victoria
  • 3083
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1ADASX (Australian Securities Exchange)YesOrdinary SharesAUAUDAug 2016
1ADCHIA (Chi-X Australia)YesOrdinary SharesAUAUDAug 2016

Biography

AdAlta Limited, a drug discovery and development company, develops protein therapeutics. The company focuses on developing its lead i-body drug candidate, AD-114, for the treatment of idiopathic pulmonary  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/21 10:41
End of Day Share Price2019/11/21 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.